Navigation Links
Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohn's Disease
Date:8/21/2013

OSAKA, Japan, Aug. 21, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") today announced that results from two Phase 3 studies evaluating vedolizumab, an investigational humanized monoclonal antibody, for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD), were published in the August 22, 2013 issue of the New England Journal of Medicine. Chronic and debilitating diseases, CD and UC are the two most common types of inflammatory bowel disease (IBD) and affect more than four million people worldwide, including approximately 1.4 million Americans and 2.2 million Europeans. Vedolizumab is designed to specifically antagonize the alpha4beta7 integrin, which is expressed on a subset of circulating white blood cells that have been shown to play a role in mediating the inflammatory process in CD and UC. 

"The publication of these study findings is important since the results support the potential for vedolizumab, if approved, to help manage symptoms in some patients for whom certain previous treatments have failed," said Brian Feagan, M.D., professor of medicine, epidemiology, and biostatistics at the University of Western Ontario, Canada and GEMINI lead investigator. "The data from the GEMINI program suggest that vedolizumab may provide people living with CD and UC an additional option for inducing and maintaining clinical remission."

In the publication, study results from GEMINI I, a placebo-controlled induction and maintenance study in patients with UC, showed that vedolizumab met primary endpoints of improvement in clinical response (reduction in the Mayo Clinic score of greater than or equal to 3 points and greater than or equal to 30 percent from baseline, along with a decrease of at least 1 point on the rectal bleeding subscale or an absolute rectal bleeding score of 0 or 1) at six weeks and clinica
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. 1st Case Report of Using Single-Site Cannulation ECMO to Treat SynCardia Total Artificial Heart Patient Published in Journal of Cardiothoracic Surgery
2. Mechanism for Cardiac Effects of Trevena Angiotensin Receptor Biased Ligands Examined in Published Study
3. Leadership Through Research Collaboration Is Reflected In Articles Published In Alzheimers Association Journal
4. Depression Study Published on BCM-95 Curcumin
5. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
6. Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
7. BioElectronics New Patent Published
8. Benefits of Using Hologics Breast Tomosynthesis Mammography Technology Supported in Published Italian Study
9. Clinical Results for Orameds Oral Diabetes Treatment Published in Peer Reviewed Journal PLOS ONE
10. Study Published in European Radiology Further Supports the Use of Hologics Breast Tomosynthesis in Cancer Screening in Practices Using Double Reads
11. Data on SEEKs Novel Immunotherapy for HIV Published in Virology Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... N.J. , Aug. 1, 2014  PTC Therapeutics, ... on July 31, 2014 it approved non-statutory stock options ... common stock to seven new employees. The awards were ... a component of our new hires, employment compensation. ... Committee on July 31, 2014 and are being made ...
(Date:8/1/2014)... , Aug. 1, 2014  With monumental health reform ... speak a second language. Clinical efficacy is no longer ... under the ACA like PCORI are directing roughly $1 ... of new entities and environments, the federal healthcare ecosystem ... new language of outcomes and managed markets to the ...
(Date:8/1/2014)... YORK , Aug. 1, 2014  Valeant Pharmaceuticals ... L.P. today responded to the filing of a federal ... in California.  The complaint makes baseless claims about Valeant ... Allergan,s true purpose in bringing the litigation ... call a special meeting.  That purpose is made clear ...
Breaking Medicine Technology:PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 2Pharmaceuticals Learning the Language of the New Healthcare Landscape 2Pharmaceuticals Learning the Language of the New Healthcare Landscape 3Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 2Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 3Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 4Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 5Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 6
... 23, 2012  Doctors and other healthcare professionals have grown increasingly ... is taking with regard to Fosamax - a widely used ... fractures. The FDA has so far resisted ... prolonged use. Such labels are necessary in light of the ...
... BEIJING, Feb. 23, 2012 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical ... an emerging leader in the development, assembly, marketing and ... announced that for the year ended December 31, 2011, ... led by the Ministry of Science and Technology of ...
Cached Medicine Technology:Victims of Abnormal Bone Fractures Await Action as FDA Lingers on Edge of Tightening Fosamax Regulations 2Dehaier Medical Received Government Subsidy as a Certified High Technology Enterprise 2Dehaier Medical Received Government Subsidy as a Certified High Technology Enterprise 3
(Date:8/1/2014)... Cannabis use among young people has spiked, with ... used marijuana at least once and 17 percent admitting to ... Drugs, Say ‘Yes to Life,’ volunteers from the Church of ... with factual information about drugs, to help reverse this alarming ... to Drugs, Say ‘Yes’ to Life,” volunteers have distributed 40,000 ...
(Date:8/1/2014)... The Judicial Panel on Multidistrict Litigation ... therapy caused strokes, heart attacks, and other injuries in ... F. Kennelly as the transferee judge and ordered what ... federal court. , As one of his first organizing ... of attorneys who will move the litigation forward on ...
(Date:8/1/2014)... San Diego School of Medicine report that dietary capsaicin ... chronic activation of a receptor on cells lining the ... the risk of colorectal tumors. , The findings are ... The Journal of Clinical Investigation . , The receptor ... sensory neurons, where it acts as a sentinel for ...
(Date:8/1/2014)... at Washington University School of Medicine in St. Louis ... males and frequently are more harmful than similar tumors ... brain tumors, are diagnosed twice as often in males, ... not survive as long. , The researchers found that ... risk, is significantly less active in male brain cells ...
(Date:8/1/2014)... a central role in regulating appetite and whole-body metabolism. ... brain,s control of food intake and body weight, but ... been unclear. A new study in the ... activity in a type of neuron known as pro-opiomelanocortin ... high-fat diet. Sabrina Diano and colleagues at Yale ...
Breaking Medicine News(10 mins):Health News:Addressing a Serious Issue Affecting German Teens 2Health News:Judge Kennelly Appoints Attorney Michelle Kranz to the Plaintiffs’ Executive Committee in the Testosterone Replacement Therapy MDL 2Health News:Pepper and halt: Spicy chemical may inhibit gut tumors 2Health News:Study reveals one reason brain tumors are more common in men 2
... the University of Warwick and the Indian Institute of Technology ... to transport iron safely through our blood stream can, in ... fibrils banded by lines of iron rust. This process could ... the brain to cause some forms of Parkinsons & Alzheimers ...
... 8 Antidepressant medications,which increase serotonin neurotransmitter ... can increase depression, impulsivity and,suicide risk in ... physicians prescribe serotonin enhancement medications to dopamine,deficient ... and,suicidal," said Dr. Rick Sponaugle, Medical Director ...
... tool powered by SNAPforSeniors(R) helps members quickly,locate safe housing, ... rash of tornadoes in more than 20 years destroyed ... Tennessee Tuesday night., Emergency warnings gave most residents ... housing, natural disasters bring extra fears. Lack,of mobility, limited ...
... NightHawk,Radiology Holdings, Inc. (Nasdaq: NHWK ), a ... United States, announced today that,the time of its fourth ... to February 13, 2008 at 4:30 p.m. (ET). The ... on February 13, 2008., Conference Call & Web ...
... (Nasdaq: MLAB ) today announced that its ... dividend of ten cents per share of common,stock, ... record at the close of,business on February 25, ... markets,electronic instruments for industrial, pharmaceutical and medical,applications., ...
... poorly one year later, study found , , FRIDAY, Feb. 8 ... sufficient reason for most people to change to a heart-healthy ... quality is poor after a coronary heart disease event," said ... at the University of Massachusetts Medical School, in Worcester. , ...
Cached Medicine News:Health News:Iron banded worms drying out of blood could be linked to Parkinson's and Alzheimer's 2Health News:Antidepressants Can Increase Depression, Impulsivity and Suicide Risk by Decreasing Dopamine 2Health News:Antidepressants Can Increase Depression, Impulsivity and Suicide Risk by Decreasing Dopamine 3Health News:Tennessee Tornadoes Spur Senior Move Managers to Aid Elderly in Crisis 2Health News:Tennessee Tornadoes Spur Senior Move Managers to Aid Elderly in Crisis 3Health News:NightHawk Radiology Holdings, Inc. Announces Time Change for Fourth Quarter and Full-Year 2007 Earnings Conference Call 2Health News:Heart Attack Seldom Leads to Healthier Diet 2Health News:Heart Attack Seldom Leads to Healthier Diet 3
... is powerful, lightweight, easy ... soft, durable foam silicone ... covered by machine washable ... headband easily adjusts to ...
... is powerful, lightweight, easy ... soft, durable foam silicone ... covered by machine washable ... headband easily adjusts to ...
Solarc surgical headlight is durable, comfortable, lightweight and delivers the bright, white light expected from a xenon system, but at a fraction of the cost....
View Mex-3 is designed for out-patient surgery, hospital rounds and house calls....
Medicine Products: